JAK Inhibitors vs Traditional Therapy for Myelofibrosis: A Meta-Analysis of Randomized Clinical Trials (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-407; "The pharmacological standard of care is the Janus kinase (JAK) inhibitor class (eg, ruxolitinib, pacritinib, momelotinib, fedratinib), which targets key disease drivers. However, traditional therapies, often grouped as best available therapy (BAT), including hydroxyurea and hematopoietic cell transplant, remain a significant comparator...The limitations in the new trials should be kept in mind while interpreting the results. CI: confidence interval, OR: odds ratio, RR: relative risk."
Retrospective data • Myelofibrosis • Myeloproliferative Neoplasm • Oncology
|
|
Maleeha Saqib MD,MBBS 1; Hassan Ijaz MBBS 2; Muhammad M Zubair MD 3; Nighat Shahbaz MBBS 4; Mustafa Malik MD,MBBS 1; Mahnoor Mahnoor MBBS 5; Sucheta Kundu MD 6
|